LIXTE BIOTECHNOLOGY HOLDINGS, INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
NMAD$3.78+5.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets - December 31, 2025 and 2024
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $5,106,872 | $1,038,952 |
| Prepaid insurance | 26,682 | 20,898 |
| Other prepaid expenses | 44,825 | 85,653 |
| Total current assets | 5,178,379 | 1,145,503 |
| LiGHT proton therapy system equipment | 6,582,560 | - |
| Right-of-use lease assets | 972,682 | - |
| Total assets | $12,733,621 | $1,145,503 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses, including $125,959 and $27,500 to related parties at December 31, 2025 and December 31, 2024, respectively | $436,482 | $83,206 |
| Research and development contract liabilities | 232,138 | 235,078 |
| Operating lease obligations, current | 595,418 | - |
| Series B Convertible Preferred Stock 8% cumulative dividend payable | 69,073 | - |
| Total current liabilities | 1,333,111 | 318,284 |
| Operating lease obligations, long-term | 438,959 | - |
| Total liabilities | 1,772,070 | 318,284 |
| Commitments and Contingencies | - | - |
| Stockholders’ Equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; | ||
| Series A Convertible Preferred Stock, $10.00 per share stated value – 0 and 350,000 shares issued and outstanding at December 31, 2025 and 2024, respectively | - | 3,500,000 |
| Series B Convertible Preferred Stock, $0.7146 per share stated value – 2,423,130 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,731,569 | - |
| Common stock, $0.0001 par value authorized – 100,000,000 shares; issued and outstanding – 8,790,102 and 2,249,290 shares at December 31, 2025 and 2024, respectively | 879 | 225 |
| Additional paid-in capital | 66,008,824 | 49,394,687 |
| Accumulated deficit | (58,077,213) | (52,067,693) |
| Total Lixte Biotechnology stockholders’ equity | 9,664,059 | 827,219 |
| Non-controlling interest | 1,297,492 | - |
| Total stockholders’ equity | 10,961,551 | 827,219 |
| Total liabilities and stockholders’ equity | $12,733,621 | $1,145,503 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.